Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.
Last updated: 2025-12-10 01:23:55 ET
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.
This survey of paving and pavement maintenance contractors helps develop an objective and verifiable listing in each of the five...
This survey of paving and pavement maintenance contractors helps develop an objective and verifiable listing in each of the five...
Forenza collaborated with data scientists and biomedical engineers to develop Awear, a small device worn behind the ear for continuous brainwave monit...
Co-founders’ acquisition of Venture Global shares before key permit granted draws scrutiny as pair deny wrongdoingTwo fossil-fuel billionaires with ...